Pharmacogenomics is the study of the role of the genome in drug response. It analyzes how the genetic makeup of an individual affects his/her response to drugs. The Dr. Antoni Esteve Foundation organized its ninth Esteve Foundation Discussion Group by bringing together nine of the leading experts in the field the past 23 and 24 May 2019 in S’Agaró. During two days of work, they analyzed the latest advances and the challenges facing pharmacogenomics. Contributions that will be part of a next scientific article.

The Esteve Foundation Discussion Group was moderated by Rachel Tyndale, from the Department of Pharmacology and Toxicology, University of Toronto, and Mary V. Relling, from the Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital and with the participation of the following professionals:

Meghan Chenoweth
Pharmacology & Toxicology, University of Toronto. Canada

Kathy Giacomini
University of California San Francisco. USA

Sue Hill
National Health Service (NHS). England, United Kingdom

Munir Pirmohamed
University of Liverpool. England, United Kingdom

Ron H.N. van Schaik
Erasmus MC, Rotterdam. The Netherlands

Matthias Schwab
Dr. Margarete Fischer‐Bosch‐Institute of Clinical Pharmacology, Stuttgart. Germany

Alan Shuldiner
Regeneron Genetics Center, and University of Maryland School of Medicine. USA